Eton Pharmaceuticals, Inc. 8K

Eton Pharmaceuticals licensed U.S. rights to late-stage infantile hemangioma candidate ASN-001 from Auson Pharmaceuticals, aiming for an NDA in 2H 2027 and potential launch in 2028 to complement its HEMANGEOL franchise.

Eton Pharmaceuticals, Inc. announced that it has acquired the U.S. license rights to ASN-001 (timolol topical gel), a late-stage rare disease product candidate for proliferating superficial infantile hemangiomas, from Auson Pharmaceuticals Inc., with prior Phase II/III data showing significant efficacy versus placebo. Eton plans to conduct a bioavailability bridging study and target a New Drug Application submission in the second half of 2027, positioning ASN-001—if approved—for potential U.S. launch in 2028 as the first FDA‑approved topical therapy for infantile hemangiomas and a complementary product to its existing HEMANGEOL (propranolol hydrochloride) oral solution franchise, leveraging its established pediatric dermatology commercial infrastructure and potentially creating the largest revenue generator in its portfolio.

Filing Facts

CIK

1710340

Ticker

-

Form

8K

Source Type

sec

Accession

0001437749-26-025781

Alert Tier

7